The insider activity is too small to signal a material change in fundamentals. Monitor for upcoming clinical catalysts or earnings to gauge the company's trajectory; the director's buying may indicate confidence, but the CEO's larger sale warrants watching for any pattern.
PALI drugs
PALI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $1.89entry
- T+1 · 4mo ago +2.12%α +1.76% · $1.93
- T+5 · 4mo ago +4.23%α +5.02% · $1.97
- T+20 · 3mo ago +11.11%α +7.93% · $2.10
- T+60 · 6w ago −21.16%α −25.16% · $1.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A small insider cluster at Palisade Bio (PALI) shows mixed activity: Director Baltera purchased ~$191K worth of shares over 7 days, while CEO/CFO Finley and CMO Jones sold a combined ~$410K in open-market transactions. The total open-market value of ~$600K represents only ~0.18% of the $342M market cap, making this cluster immaterial and routine for a micro-cap biotech.
Key Financial Metrics
Key Facts
- Director Baltera Robert Jr. made four open-market purchases totaling ~$191K at ~$1.96-$2.05/share.
- CEO/CFO Finley John David sold 146,798 shares open-market for ~$303K, plus exercised derivatives (non-cash).
- CMO Jones Mitchell Lawrence sold 51,880 shares open-market for ~$107K, plus exercised derivatives (non-cash).
- Total open-market sales ($410K) exceeded purchases ($191K), but both are <0.2% of market cap.
- No 10b5-1 plan or blackout window context is provided; sales could be liquidity-driven.
Financial Impact
Net insider selling of ~$219K (sales minus purchases) is trivial relative to $342M market cap.
Risk Factors
- CEO and CMO selling concurrently could indicate near-term bearish sentiment, though amounts are small.
- No explicit guidance or catalyst in the cluster; share price may be influenced by other news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PALI-1783721693815 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Viewing Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers